| Document |
Document Title |
|
WO/2004/058733A1 |
The invention relates to compounds of general formula (I) and the use thereof for producing medicaments that are utilized for treating and preventing diseases which are accompanied by inflammatory, allergic, and/or proliferative processes.
|
|
WO/2004/052372A1 |
The present invention provides for compounds of formula (I), (la) and (lb) Wherein: A is selected from C-X and N, B is selected from C-Y and N, R1 is selected from H and (C1-C6)alkyl R2 is selected from H and (C1-C6)alkyl, X is selected ...
|
|
WO/2004/052360A1 |
The present invention relates generally to prodrugs of fused GABA analogs, pharmaceutical compositions of prodrugs of fused GABA analogs, methods of making prodrugs of fused GABA analogs and methods of using prodrugs of fused GABA analog...
|
|
WO/2004/052871A1 |
Benzomorpholine derivatives typified by compounds represented by the following general formula (VIII), pharmaceutically acceptable salts thereof and platelet aggregation inhibitors comprising the same. Because of having a potent effect o...
|
|
WO/2004/050623A1 |
Methods of making substituted phenylalkynes of formula (I).
|
|
WO/2004/048335A2 |
The invention is concerned with novel mandelic acid derivatives of formula (I), wherein R1 to R10, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit ...
|
|
WO/2004/046124A1 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed:wherein A, R1, R2, R3, p, q, A and X are as defined in the specification. Preparation of the compounds and uses in the treatment of CNS and other disord...
|
|
WO/2004/046138A1 |
The invention relates to novel compounds of formula (I) wherein D, W, X, Y, T, m and R1 have the designations cited in patent claim 1. Said novel compounds are inhibitors of the coagulation factor Xa and can be used for the prophylaxis a...
|
|
WO/2004/046119A1 |
The present invention relates to novel substituted aralkyl derivatives of the general formula (I) & (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically accepta...
|
|
WO/2004/045618A2 |
The invention relates to the use of compounds of general formula (I), where the groups R1, R2 and R3 can have the meanings as given in the claims and description, for the production of a medicament for the treatment of COPD (Chronic Obst...
|
|
WO/2004/041792A1 |
The invention provides compound of the Formula (I) and pharmaceutically acceptable salts or prodrugs thereof, wherein Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, m, n, p and q are as defined herein. The invention also provides methods for ...
|
|
WO/2004/035556A1 |
The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders ...
|
|
WO2003099284B1 |
Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes,...
|
|
WO/2004/026292A1 |
Antitussives containing as the active ingredient compounds represented by the general formula (I) or salts thereof: (I) (wherein A is alkoxycarbonylalkyl or the like and R is optionally protected hydroxyl, or A and R may be united to for...
|
|
WO/2004/017977A2 |
Compounds of formula (I), wherein: A is S or O; R is H; Ar is an optionally substituted phenyl group; X is an optionally substituted phenyl group, a C1-C4 alkyl, a C3-C6 cycloalkyl group or a CH2(C3-C6 cycloalkyl) group; R' is H or C1-C4...
|
|
WO/2004/018441A1 |
Compounds of formula (I) are selective inhibitors of the reuptake of norepinephrine, wherein Rx is H; Ry is H or C1-C4 alkyl; each Rz is independently H or C1-C4 alkyl; X represents O; Y represents OH or OR; R is C1-C4 alkyl; and Ar1 and...
|
|
WO/2004/018440A1 |
A compound of formula (I) (I)wherein R is H; Ar is an aromatic group selected from phenyl; X is a phenyl group; R' is H or C1-C4 alkyl; each R1 is independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof.
|
|
WO/2004/018414A2 |
The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X=NH Y=CO, CS, -C(=N-CN) or X and Y together form an alkene, or C3-C5 cycloalkyl; R1 is -COOH; R2 is an electron withdrawing g...
|
|
WO/2004/016578A2 |
The present invention concerns compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, wherein: R1 is hydrogen or -XSO2NR6R7; R2 and R3 are independently selected from hydrogen, C1-6 alkyl, C1-6 ...
|
|
WO2003057679A9 |
The present invention provides oxazine compounds having aromatic, heteroaromatic, or aliphatic substituents at the 2 position of the oxazine moiety. Additionally, a one pot method with excellent yields is provided for producing the compo...
|
|
WO/2004/016576A1 |
A compound represented by the general formula (I) [wherein ring A represents an optionally substituted 5- to 8-membered ring; ring B represents a further optionally substituted 4- to 10-membered ring; ring C represents a further optional...
|
|
WO/2004/016272A1 |
This patent application describes a method for treating or preventing hot flashes in a patient suffering therefrom comprising administering a therapeutically effective dose of a compound selected from reboxetine, S,S-reboxetine or pharma...
|
|
WO2002098424B1 |
Compounds useful as HCV anti-infectives having the formula: wherein the formula variables are as defined herein, are disclosed. Also disclosed are methods of making and using the same.
|
|
WO/2004/014389A1 |
This invention provides compounds'defined by Formula I or a pharmaceutically acceptable salt thereof,wherein Rt, Q, Y1, Y5, Y6, Y8, R2, R2a, and R4 are as defined in the specification. The invention also provides pharmaceutical compositi...
|
|
WO/2004/014871A1 |
Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes,...
|
|
WO/2004/014880A1 |
This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, y2, y3, Y4, U5, U6, U8, and R2 are as defined in the specification. The invention also provides pharmaceutical compositi...
|
|
WO/2004/011423A2 |
A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid structura...
|
|
WO/2004/011447A2 |
A method for preparing a fused oxazinone is disclosed in which (1) a carboxylic acid is contacted with a sulfonyl chloride in the presence of an optionally substituted pyridine compound, the nominal mole ratio of sulfonyl chloride to car...
|
|
WO/2004/006850A2 |
The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms,...
|
|
WO/2004/007407A2 |
The present invention includes methods and compositions for increasing the fluorous nature of an organic compound by reacting it with at least one fluorous compound to produce a fluorous tagged organic compound. The increased fluorous na...
|
|
WO/2004/005255A1 |
The present invention relates to heterocyclic derivatives of formula (1) wherein R1 represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or...
|
|
WO/2004/002463A2 |
Disclosed is use of reboxetine in combination with a smoking-cessation enhancing agent for promoting smoking cessation. Also disclosed is a composition comprising reboxetine and a smoking-cessation enhancing agent for use for promoting s...
|
|
WO/2004/000322A1 |
A compound selected from those of formula (I): wherein: • X1, X2, and X3 represent nitrogen or -CR3 in which R3 represents hydrogen, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy, or halogen, • Gl represents oxygen or S(O)p...
|
|
WO/2004/000771A1 |
The invention relates to 3,3,4,4-tetrafluorocyclopentane compounds of formula (I), in which R1, A1, A2, Z1, Z2 and m are defined as cited in claim 1. Said compounds are suitable for use as components of liquid crystal media.
|
|
WO/2004/000321A1 |
A compound selected from those of formula (I) wherein: X¿1?, X¿2? and X¿3? represent nitrogen or -CR¿3? in which R¿3? represents hydrogen, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy, or halogen, G¿1? represents oxygen ...
|
|
WO/2004/000230A2 |
The present invention provides for the use of a compound of formula (I) or formula (II) in treating skin disorders, wherein formula (I) is: and wherein R1-R5 and Q1 are defined as described herein. Specifically, methods for treating acne...
|
|
WO/2003/105855A1 |
The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relat...
|
|
WO/2003/106440A2 |
The invention relates to a process for the synthesis of mosapride citrate of formula (I): (R,S)-4-amino-5-chloro-2-ethoxy-N-&lcub [4-(4-fluoro-benzyl)-2- morpholinyl]-methyl&rcub benzamide citrate dihydrate.
|
|
WO/2003/106441A1 |
The present invention relates to novel crystalline, water-soluble salts of the 2S,3S enantiomer of reboxetine, which are the fumarate and succinate salts thereof, to a process for their preparation, to their utility in therapy and to pha...
|
|
WO/2003/104210A1 |
The present invention relates to chromophores for selective staining of cells or cell parts comprising a fluorescent chromophore of the general formulae I. The invention further comprises a method for cell sorting, a method for cell targ...
|
|
WO/2003/103656A1 |
Drugs having inhibitory activity against NF-κB activation, containing as the active ingredient substances selected from the group consisting of compounds represented by the general formula (I), pharmacologically acceptable salts thereof...
|
|
WO/2003/099798A1 |
Compounds of formula (I): wherein:R1 represents C3-8 cycloalkyl-Y1-, aryl-Y1-, heteroaryl-Y1-, aryl- G-Y1-, heteroaryl-G-Y1-, C1-6 alkyl-G-Y1-, J1-Y1-, R22R23N-Y1-, R22R23N-CO-Y1- or R24-CONR22-Y1-; Q represents -(CR19R20)(CR19aR20a)t-, ...
|
|
WO/2003/099287A1 |
Compounds of formula I: (I) wherein:R1 represents C3-8 cycloalkyl-Y1-, aryl-Y1-, heteroaryl-Y1-, aryl- G-Y1-, heteroaryl-G-Y1-, C1-6 alkyl-G-Y1-, J1-Y1-, NR21R22-Y1-, NR21R22-CO-Y1- or R23-CONR21-Y1-;Q represents -(CR16R19)(CR18aR19a)t-,...
|
|
WO/2003/097618A1 |
Compounds of formula (I'): (I); wherein: R1 represents substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X represents -(CRkaRkb)k-; Rka and Rkb are each independently hydrogen or C1-6alkyl; k is 0-5; Y represe...
|
|
WO/2003/095434A1 |
The present invention provides a compound which has 5-HT6 receptor affinity of the formula (I): a pharmaceutically acceptable salt or a prodrug thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Z1, m, n, and p are as defined herein. ...
|
|
WO/2003/094918A1 |
Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutical...
|
|
WO/2003/093235A1 |
Novel compounds of formula (I), wherein D, W, X, Y, T and R1 have the meanings as cited in Patent Claim 1, are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or therapy of thromboembolic diseases and for the ...
|
|
WO/2003/093254A1 |
The invention relates to novel compounds of formula (I), wherein R, R1, R1', X and T have the meaning given in patent claim 1. Said novel compounds are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or therap...
|
|
WO/2003/093242A2 |
The present invention relates to substituted 5-membered polycyclic compounds and prodrugs thereof, compositions and methods useful for preventing and treating thrombotic conditions in mammals. The compounds of the present invention, and ...
|
|
WO/2003/090690A2 |
Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit HIV protease activity and/or are useful therapeutically for th...
|
